rsv f

Ziresovir (RO-0529/AK0529) belongs to small molecule inhibitors and is a respiratory syncytial virus (RSV) fusion protein (F protein) inhibitor (EC50 = 3 nM) with oral activity and selectivity. This compound is used in research on respiratory syncytial virus infection, significantly alleviating bronchitis symptoms and reducing viral load.

Anti-Human respiratory syncytial virus (RSV) Fusion Glycoprotein/RSV-F Antibody (1B191) is a Rabbit IgG monoclonal antibody targeting RSV Human respiratory syncytial virus (RSV) Fusion Glycoprotein/RSV-F.

Anti-RSV-F Antibody (AM22) is an antibody. Its expression system is CHO cells, the clone number is AM22, and the isotype control is IgG1, Kappa.

Anti-RSV-F/HMPV-F Antibody (MPE8) is a CHO-expressed IgG1λ monoclonal antibody that targets and neutralizes RSV-F/HMPV-F, suitable for respiratory virus research.

Anti-RSV-F Antibody (4D7) is an antibody. Its expression system is CHO cells, the clone number is 4D7, and the isotype control is IgG1, Kappa.

CGR-50 is an inhibitor of the respiratory syncytial virus (RSV) fusion glycoprotein (F protein) with an EC50 of 19.4 nM against the RSVA2 strain in HEp-2 cells. It prevents RSV entry by binding to the F protein and inhibiting membrane fusion. CGR-50 is applicable in studies related to RSV infections.

BMS-433771, a novel inhibitor of respiratory syncytial virus (RSV), binds the RSV F glycoprotein and inhibits membrane fusion.

JNJ-2408068 is an inhibitor of respiratory syncytial virus (RSV). JNJ-2408068 exhibited potent antiviral activity with EC50 of 2.1 nM. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50= 0.9 nM). JNJ-2408068 interferes with

RSV-IN-5 is a potent dual inhibitor of wild-type and mutant respiratory syncytial virus (RSV) fusion proteins.RSV-IN-5 was able to act on wild-type A2 F protein and D486N mutant F protein with EC50 values of 2.0 nM and 8.1 nM, respectively, and exhibited potent anti-RSV effects.

Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).

Felvizumab (SB 209763), a humanized IgG1κ monoclonal antibody, targets specific neutralizing epitopes on the F glycoprotein of Respiratory Syncytial Virus (RSV) [1] [2].

Gontivimab (ALX-0171) is a trivalent nanobody targeting the hRSV fusion (F) protein with anti-RSV antiviral properties for the study of respiratory syncytial virus infections.

Sisunatovir hydrochloride (RV521 HCl) is an orally available inhibitor of the RSV-F protein that has exhibited potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses in vitro (IC50 = 1.4 nM for RSV-A, IC50 = 1.0 nM for RSV-B).

RSM01 is a pan-human monoclonal antibody that targets a site in the RSV pre-F region and carries a YTE mutation that prolongs its half-life. RSM01 exhibits activity against respiratory syncytial virus (RSV) and can be used in research on lower respiratory tract infections (LRTI).

VIR-8190 is a human IgG1 monoclonal antibody targeting the fusion glycoprotein F0. It is utilized in the study of respiratory syncytial virus (RSV) and metapneumovirus infections. The recommended isotype control is Human IgG1 kappa [Isotype Control].

IN-002 is a human monoclonal antibody targeting the F, FusionglycoproteinF0. It is used in the study of respiratory syncytial virus (RSV) infection.

EVO-46120 is a human monoclonal antibody that targets the F, FusionglycoproteinF0. It is used in research related to respiratory syncytial virus (RSV) and pneumovirus infections.

AR-201 is a human IgG1 monoclonal antibody that targets the F glycoprotein F0. It exhibits activity against the respiratory syncytial virus (RSV) and can be utilized in studies related to lower respiratory tract infections (LRTI). The recommended isotype control is HumanIgG1kappa, Isotype Control.

Glarivibart is a humanized IgG1κ monoclonal antibody inhibitor that targets the fusion F protein (RSV-F) of respiratory syncytial virus (RSV). It exhibits significant antiviral activity and is applicable for RSV infection research.

Retavibart is a fusion protein (glycoprotein F) of the human respiratory syncytial virus (RSV). It can be used for antiviral research.